Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS (NASDAQ:ALXO)
Earnings Name Insights: ALX Oncology (ALXO) Q1 2026 Administration view Searching for Alpha's Disclaimer: This text was routinely generated by ...



-1024x683.jpg?w=120&resize=120,86&ssl=1)


